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ABSTRACT 
QUALITY IMPROVEMENT IN STROKE CARE AND ITS IMPACT: THE GEORGIA 
COVERDELL ACUTE STROKE REGISTRY EXPERIENCE 
by 
MOGES SEYOUM IDO, MD, MS, MPH 
June 22, 2016 
The Georgia Department of Public Health has been engaged in a registry-based quality 
improvement initiative to monitor and improve the quality of stroke care. It is important to 
evaluate effectiveness of the quality improvement initiative in order to expand the effort to other 
sites or disease conditions. The studies, included in this dissertation, addressed whether acute 
ischemic stroke patients cared for by hospitals participating in the Georgia Coverdell Acute 
Stroke Registry (GCASR) had a better survival than those treated at other facilities, assessed 
whether quality of care as measured by nationally accepted ten performance measures is 
associated with improved patient outcome and evaluated the impact of intravenous alteplase 
treatment on 1-year mortality. 
Three data sources – GCASR, Georgia Discharge Data System and the death data – were 
used for analyses. These data sources were linked applying both a hierarchical deterministic and 
a probabilistic linkage methods. Survival after stroke incident was analyzed using the extended 
Cox proportional hazard model. Generalized estimating equation (glimmix procedure) and 
conditional logistic regression were applied, respectively, to assess the association of quality of 
care and intravenous alteplase use with 1-year mortality. 
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Acute ischemic stroke patients treated at nonparticipating facilities had a hazard ratio for 
death of 1.14 (95% confidence interval, 1.03–1.26; P-value = .01) after the first week of 
admission compared with patients cared for by hospitals participating in the registry. Among 
patients treated in GCASR-participating hospitals, patients who received the lowest and 
intermediate quality care respectively had a 3.94 (95%CI: 3.27, 4.75; p-value <0.0001) and a 
1.38 (95%CI: 1.12, 1.62; p-value=0.002) times higher odds of dying in one year compared to 
those who got the best quality stroke care. Patients who were eligible but did not receive IV 
alteplase had a 1.49 (95%CI: 1.09-2.04; p-value=0.01) times higher odds of dying within one 
year than those who were treated with the thrombolytic agent. 
The results strongly suggest that registry-based quality improvement effort has brought 
significant improvements in ischemic stroke patients’ outcomes. Therefore, it is critical that 
hospitals adopt a quality improvement strategy to change the process of care delivery for a better 
patient outcome.  
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CHAPTER I 
INTRODUCTION 
Quality Improvement 
Healthcare providers strive to improve the quality of patient care and enhance their 
performance. The assessments and continuous systematic efforts to improve quality of care 
constitute quality improvement.1 Quality improvement is data driven, focuses on patients’ need 
and expectations, and works on processes and systems of healthcare delivery.1 In most healthcare 
setups, particularly where multiple units play a role in the process of healthcare delivery, it 
requires a team effort involving every unit of the organization to improve the quality of patient 
care. 
The Institute of Medicine (IOM) defines quality of care as “the degree to which health 
services for individuals and populations increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge.”2 Quality of care encompasses every aspect 
of healthcare – diagnostic, therapeutic and preventive – both in a clinical and community setup. 
Delivery of a clinical care has three dimensions: the environment in which the care is provided 
(the structure); the actual care including patient reception, diagnosis, treatment, preventive care 
and discharge instruction; and the outcome in terms of patient health status, satisfaction, and 
behavior and resource consumption.3 Measurement of the factors in each dimension of care 
delivery may not be sufficient to evaluate quality of care unless they can be shown to relate to 
indices of quality. 
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The IOM’s definition implies that quality is inherent to any health service and the care 
has to be congruent with the best available evidence-based practices and guidelines. Adherence 
to these guidelines need to be monitored continuously to ensure that patients receive the best care 
at all times. Measuring healthcare providers’ performance requires continuous systematic data 
collection and analysis, and performance measures to assess whether the provider is attaining the 
goal set for healthcare delivery process. 
Despite rapid advances in medical science and technology, not all patients consistently 
receive high quality clinical care. A study among American adults in 12 metropolitan cities 
indicated that patients received only 55% of the recommended care.4 Almost two decades after 
FDA approved the use of thrombolytics for ischemic stroke patients, only 12% of the patients 
receive the treatment in Georgia.5 Thus, medical advances and the availability of resources do 
not necessarily translate into provision of high quality care to all patients over time. It is, 
therefore, necessary to design strategies for dissemination and broad scale application of 
evidence based clinical practices. How states organize their healthcare system or how healthcare 
providers set up delivery of care taking a system’s perspective becomes important in meeting 
patients’ expectation and expectations of the community at large. 
Replication and implementation of an intervention require demonstration of effectiveness 
in a broader use. Despite evidence of effectiveness, hindrance to implementation could come 
from lack of information about the new strategy on quality of care or from reluctance to accept 
the new clinical care guidelines.6-8 Strong evidence demonstrating the effectiveness of an 
intervention would facilitate buy-in from healthcare facilities and their practitioners. Therefore, it 
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is essential to measure, evaluate and document the changes brought by interventions targeting 
quality of care and its purported impact on patient outcomes. 
Strategies to implement evidence based medicine has evolved from the optimistic passive 
diffusion where we assume clinicians would adopt a new clinical practice if they are provided 
with the information to a more active approach of quality improvement.9 The concept of quality 
improvement is not unique for clinical care or healthcare in general; rather, the industrial sector 
is the vanguard in implementing methods of quality improvement for better productivity 
(efficiency) and ensuring product quality.10 Methods of quality improvement tried and tested in 
other sectors have also been shown to be applicable in clinical care11,12 as well because the 
ultimate target remains the same – better outcome in the most efficient way.  
Studies have shown that implementation of quality improvement activities lead to 
improvement in the process of care delivery and patient’s outcomes.13-23 These studies involved 
healthcare facilities of different levels and various clinical conditions from infectious disease to 
chronic conditions such as depression and diabetes mellitus. They documented improvements in 
adoption of care processes and uptake of evidence-based guideline recommendations including 
prescription of appropriate medications, reduction in unnecessary referrals, narrowing the gap in 
gender and racial disparity in health outcomes, reducing complications, secondary disease 
prevention and better patient outcomes in terms of disease control, readmission rate and 
mortality. 
Some studies, however, failed to demonstrate significant improvement both in patient 
care process and outcome resulting from QI activities.24-26 A review of literature on the impact of 
quality improvement initiatives concluded that the effect of a quality improvement undertaking 
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cannot be predicted with certainty.24 The reviewers examined 72 papers from 1,101 published on 
quality improvement from 1995 to 2006, and were only able to show that quality improvement 
collaborative would improve care process, organizational performance, access to care and 
consumer satisfaction but not the outcome. Therefore, it is important to evaluate such initiatives 
using outcome measures both for the purpose of long-term, large scale implementation and for 
identifying components of the quality improvement initiative with the greatest relationship to 
those outcomes, even if they were launched initially based on available scientific evidences. 
In the context of clinical care, ensuring clinicians adhere to evidence-based clinical 
guidelines is part of a quality improvement task. Guidelines usually are institution-based, but in 
some cases there are guidelines developed by experts or professional associations that are also 
endorsed and recommended by national institutions. It is expected that such guidelines would be 
readily disseminated to healthcare providers and easily adopted, although the environment in 
which the care is provided and the processes involved in implementing national guidelines must 
be considered. However, the basic question –whether or not adherence to clinical guidelines in 
stroke care results in better patient outcome – remain unanswered.  
The Georgia Coverdell Stroke Registry 
Stroke is the fifth leading cause of mortality in the United States.27 Every year, around 
800,000 people develop acute stroke28 and about 70% of the survivors develop some residual 
disability including neurological deficit, speech disorder, cognitive deficit or psychological 
disorder such as depression.29 Stroke not only affects the individual patient but adds economic and 
emotional burden to their caregivers and the community at large.30,31 In the United States, the direct 
and indirect costs of stroke amounted to 36.5 billion dollars in 2010.28 
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In 2001, the United States Congress directed the Centers for Disease Control and 
Prevention (CDC) to establish a state-based acute stroke registry to measure and monitor the 
quality of acute stroke patient care.32 After three years of piloting, the state of Georgia received a 
grant to set-up a registry which is currently housed in the Department of Public Health (DPH). 
Since then, DPH, in collaboration with its partners, has been assisting more than 60 hospitals to 
improve the quality of stroke patient care. Different size hospitals ranging from critical access to 
large teaching hospitals participate in the registry; currently, about 80 percent of stroke patients 
are treated at GCASR participating hospitals. 
A wealth of scientific evidences shows that improvement in specific elements of clinical 
care could result in better patient outcome.33 The Georgia Coverdell Acute Stroke Registry 
(GCASR) encourages hospitals to adopt a quality improvement program and provides technical 
assistance through regular trainings, workshops, site visits and direct one-on-one consultations, 
data feed-back, mentorship and sharing the best practices to ensure that every patient in Georgia 
receives the best evidence-based clinical care. 
The Institute of Medicine’s definition of quality of care puts emphasis on health outcome 
as indicators of quality, although information on the type, level and amount of healthcare 
provided to the community is also essential. Outcome measures may not be as sensitive as 
process measures in showing immediate changes made in quality improvement initiatives; 
however, they are necessary to show that the change in process measures results in benefits to 
patients.34 
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STUDY OBJECTIVES 
GCASR has registered significant improvements in the quality of care provided in 
participating hospitals.35,36 Based on the 2005-2009 hospital discharge data, ischemic stroke 
patients cared for by GCASR hospitals had a 64% higher odds (OR=1.64) of receiving 
intravenous thrombolysis. However, it needed to be seen whether patients cared for by hospitals 
participating in GCASR had better outcome and if this improvement in patient outcome could be 
attributed to the quality improvement measures undertaken by the participating hospitals. The 
main objective of this study, therefore, is to assess the direct impact of the quality improvement 
program on short and/or long term outcomes – ambulatory status at discharge, readmission and 
death. 
Objective 1.  Do acute ischemic stroke patients treated at GCASR hospitals have a better 
survival than patients cared for by non-participating hospitals? 
Objective 2.  Does quality improvement as measured by the ten performance measures reduces 
the 1-year mortality of acute ischemic stroke patients? 
Objective 3.  Does intravenous alteplase affect mortality among acute ischemic stroke patients? 
The results will help to expand the program to non-participating hospitals in Georgia and 
for other states to learn from and replicate Georgia’s experience. The studies required linking 
three data sources – the GCASR data, the Georgia Discharge Data system (GDDS - hospital 
discharge data) and the Death Records – related to the care and outcome of stroke patients in 
Georgia. GCASR and GDDS data from 2008 to 2013 and death data from 2008 to 2014 were 
linked and analyzed. The data sources have variables on patient demography, disease status, 
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treatment, facility and event-related information. This experience of linking registry and 
administrative data will serve as a blue print for evaluation of other public health programs based 
on clinical care. 
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CHAPTER II 
Administrative Data Linkage to Evaluate a Quality Improvement Program in Acute 
Stroke Care, Georgia, 2006 – 2009 
ABSTRACT 
Introduction 
Tracking the vital status of stroke patients through death data is one approach to assessing 
the impact of quality improvement in stroke care. We assessed the feasibility of linking Georgia 
hospital discharge data with mortality data to evaluate the effect of participation in the Georgia 
Coverdell Acute Stroke Registry on survival rates among acute ischemic stroke patients. 
Methods 
Multistage probabilistic matching, using a fine-grained record integration and linkage 
software program and combinations of key variables, was used to link Georgia hospital discharge 
data for 2005 through 2009 with mortality data for 2006 through 2010. Data from patients 
admitted with principal diagnoses of acute ischemic stroke were analyzed by using the extended 
Cox proportional hazard model. The survival times of patients cared for by hospitals 
participating in the stroke registry and of those treated at nonparticipating hospitals were 
compared. 
Results 
Average age of the 50,579 patients analyzed was 69 years, and 56% of patients were 
treated in Georgia Coverdell Acute Stroke Registry hospitals. Thirty-day and 365-day mortality 
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after first admission for stroke were 8.1% and 18.5%, respectively. Patients treated at 
nonparticipating facilities had a hazard ratio for death of 1.14 (95% confidence interval, 1.03–
1.26; P-value = .01) after the first week of admission compared with patients cared for by 
hospitals participating in the registry. 
Conclusion 
Hospital discharge data can be linked with death data to assess the impact of clinical-
level or community-level chronic disease control initiatives. Hospitals need to undertake quality 
improvement activities for a better patient outcome 
.  
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INTRODUCTION 
Assessing the impact of chronic disease programs and the quality of clinical care for 
patients with chronic diseases is essential to identify areas for improvement in care and to 
demonstrate the level and nature of improvements already made.37 The American Heart 
Association/American College of Cardiology Working Group on Quality of Care and Outcomes 
Research in Cardiovascular Disease and Stroke advocates measuring the short-term and long-
term outcomes of quality of care for stroke patients as a way of determining the impact of related 
chronic disease programs.38 Tracking the vital status of patients with chronic disease, who may 
be seen at different health facilities, by using death data is a promising method for assessing the 
overall quality of care for chronic diseases.37 
Administrative data such as hospital discharge data and death data are great resources for 
public health studies.39–41 These are population-based databases that can be used to assess the 
quality of stroke care because they include all population groups. Administrative data are easy to 
access, and they provide longitudinal information for passive follow-up and trend analyses. 
The Georgia Coverdell Acute Stroke Registry (GCASR) is a part of a national stroke 
registry program, the Paul Coverdell National Acute Stroke Registry. The national registry has 
the long-term goal of reducing premature deaths attributable to stroke and preventing stroke 
disability and recurrent stroke through ensuring the highest quality of acute stroke care to all 
Americans. GCASR was launched by the Georgia Department of Public Health in 2005 in 
partnership with other stakeholders. We sought to assess the feasibility of linking mortality data 
from the Georgia Department of Public Health Office of Vital Records with hospital discharge 
data from the Georgia Hospital Association’s Georgia Discharge Data System (GDDS) and to 
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evaluate the impact of participation in a state-based registry program on survival of patients with 
acute ischemic stroke. 
METHODS 
Georgia death records and Georgia hospital discharge data 
The Georgia Department of Public Health Office of Vital Records is responsible for 
collecting information about deaths among Georgians by using the death certificates. The death 
certificate contains information on individuals’ demographic characteristics, residence, 
underlying possible causes of death, location of death, and death date. Each year, more than 
67,000 Georgians die, and 98% of the deaths occur within the state of Georgia. 
The GDDS is housed at the Georgia Hospital Association and has information on all 
inpatients discharged from nonfederal short-stay hospitals in Georgia. GDDS gathers more than 
a million records per year. GDDS and mortality data share common variables including age, sex, 
race, residence information, and a quasi-unique subject identifier (LONGID) that facilitates the 
data linkage. 
The feasibility of data linkage is based on the assumption that the variable LONGID was 
sufficiently specific to distinguish each subject in the data sources. The LONGID is a 15-digit 
alphanumeric unique code created from letters of patients’ first and last names, birth date, and 
sex. We tested accuracy of data linkage by using data from GDDS for 1,494 Georgia patients 
who were admitted to a hospital for acute stroke and who died as a result (International 
Classification of Diseases, Ninth Revision [ICD-9]) codes 430–436) in 2006 and for 3,598 
patients with similar age characteristics (patients with malignant neoplasm of respiratory and 
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intrathoracic organs: ICD-9 codes 160–165) but who were alive in 2006. Patients with similar 
age characteristics were chosen because personal name patterns in a given community may 
change through time. 
The test data set was then linked with the Georgia mortality data for 2006 by using a 
multistage deterministic and probabilistic matching algorithm and various combinations of key 
variables (Table 1 and Table 2). We used fine-grained record integration and linkage software 
for matching, and we excluded duplicate entries using the LONGID, admission and discharge 
dates, and facility codes.42 Degrees of linkage between hospital discharge data and mortality data 
were determined (Table 3). 
Assessment of impact of stroke registry – survival analysis 
We used the 2005 through 2009 GDDS and the 2006 through 2010 Georgia Office of 
Vital Records mortality data to examine the survival rates of acute ischemic stroke patients. 
Patients admitted to nonfederal acute care and critical access facilities with the principal 
diagnosis ICD-9 codes 433 and 434 were identified and linked to the death data. Death and 
survival time from the index admission date, regardless of the underlying cause of death, were 
the outcome variables. We believe that care in the first few hours after stroke symptom onset 
determines the stroke patient’s subsequent health condition, so we attributed the outcome to the 
facility of first stroke admission. Patients were labeled to have had a first stroke admission in 
2006 if they were not admitted for any type of stroke, ICD-9 codes 430–438, in 2005. 
We defined enrollment in GCASR if the hospital actively participated in data entry and 
quality improvement activities. We considered patients to have had stroke care by a GCASR 
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facility if the hospital in which patients were admitted was enrolled in the registry. Patients who 
were treated at any time before a facility was enrolled or after it withdrew its participation were 
counted as patients treated by a non-GCASR hospital. We included patient’s sociodemographic 
characteristics such as age, sex, race, insurance status, and length of hospital stay, and hospital 
features including number of beds and location as covariates in the analysis. On the basis of the 
number of beds, we classified hospitals as small (<100 beds), medium-small (100–249 beds), 
medium-large (250–399 beds) and large hospitals (≥400 beds). We used the Rural-Urban 
Commuting Area classification of location to classify hospitals geographically into metropolitan 
(codes 1–3) and nonmetropolitan (codes >3).43 
Comorbidities were included in the analyses to adjust for disease severity. We used the 
Healthcare Cost and Utilization Project software from the Agency for Healthcare Research and 
Quality (US Department of Health and Human Services) to define comorbidities for each patient 
based on the ICD-9 codes in the hospital discharge data.44,45 Patients’ readmission status before 
either the end of the follow-up period or the patient’s death was captured from the hospital 
discharge data, and we classified patients as either not having been readmitted, readmitted to the 
same hospital, or readmitted to a different hospital. If patients were admitted to a different 
hospital within a day after their index or first admission date we considered their status as a 
transfer rather than a readmission, and they were excluded from the analysis. All the variables 
used in the analyses refer to what was documented at the first stroke admission except for the 
date of death. To have stable estimates, we excluded stroke patients from hospitals with fewer 
than 15 patients over the study period. 
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Statistical analysis 
We analyzed the data by using SAS for Windows (version 9.3, SAS Institute, Inc). We 
assessed the sensitivity of the linkage procedure based on the proportion of stroke-related in-
hospital deaths that were captured by the 2006 Georgia vital records mortality data. We 
determined specificity by the proportion of subjects who were admitted in 2007 having a 
malignant neoplasm of the respiratory organs that were linked to any of the records in the 2006 
death file. We assessed patient and hospital characteristics descriptively and tested differences 
between patients treated at GCASR participating and nonparticipating hospitals using χ2 tests for 
nominal variables and Wilcoxon tests for quantitative variables. 
We assessed the proportional hazard assumption graphically and through the goodness-
of-fit test for correlation between the Schoenfield residuals and failure time.46 We repeated the 
graphic assessment using the log–negative log of survival curves after adjusting for covariates. 
The GCASR participation variable did not satisfy the proportional hazard assumption. Thus, we 
analyzed survival time in correlated data using the extended Cox proportional hazard model with 
the robust sandwich estimate option to estimate the marginal covariate effects. We performed the 
analysis with and without censoring at 1 year. Results are presented indicating the hazard ratio 
for death in the first year after the seventh day of the first stroke admission date by different 
patient and hospital characteristics, including participation in GCASR. 
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RESULTS 
Data linkage test for accuracy 
Of the 1,494 acute stroke patients with an in-hospital death recorded in the 2006 hospital 
discharge data, 1,381 (92.4%) were identified in the 2006 death data, whereas none of the 3,598 
patients with malignant neoplasm of respiratory and intra-thoracic organs diagnosed in 2007 
were linked to the 2006 death data. Agreements between hospital discharge records and death 
data were high (>91%) for demographic variables, facility (93.6%), and discharge or death dates 
(92.6%) (Table 3). 
Impact of participation in state-based stroke registry: survival analysis 
From the initial 50,937 patients listed, 358 were excluded because 269 were considered 
transfers and 89 were from hospitals with fewer than 15 cases. Analysis was performed for 
50,579 acute ischemic stroke patients (Table 4) admitted to 131 acute care and critical access 
hospitals in Georgia to assess the impact of participation in GCASR during 2006 to 2009. Most 
(52%) were women, and whites accounted for two-thirds (66%) of the patients. The mean age for 
first stroke admission was 69 years. Most (64%) had Medicare as their principal health insurance 
coverage. The median hospital length of stay was 3 days. 
GCASR-participating hospitals treated 56% of the ischemic stroke patients (n = 28,077), 
and there were no statistical differences in age, hospital length of stay, proportion of various 
racial groups, or proportion of subjects with insurance coverage between patients treated at 
GCASR and non-GCASR hospitals (Table 4). However, non-GCASR hospitals were more likely 
to see female stroke patients, have less than 100 beds, to be in nonmetropolitan areas, and record 
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more stroke-related deaths at 30 and 365 days following stroke admissions. The overall mortality 
at 30 days and 365 days after the first admission were 8.1% and 18.5%, respectively. 
The extended Cox model indicated that patients treated at non-GCASR hospitals had a 
hazard ratio of 1.14 (95% confidence interval [CI], 1.03–1.26) from the eighth day after 
admission to 1 year after admission (Table 5). A similar hazard ratio (1.13; 95% CI, 1.04–1.22) 
was observed when no cutoff date was applied. Similarly, older patients and those treated in 
nonmetropolitan hospitals had a higher hazard ratio than their counterparts. Patients with a 
private insurance or self-pay had a lower hazard ratio than did Medicare patients. In addition, 
hospitals with fewer than 100 beds and longer hospital stays for patients were independently 
associated with subsequent death (Table 5). 
DISCUSSION 
Acute ischemic stroke patients cared for by hospitals participating in GCASR had a better 
outcome than their counterparts in nonparticipating hospitals. This study found a modest (14%) 
increase in the hazard ratio for death in the first year for patients treated at non-GCASR 
participating facilities. Several studies have shown that quality improvement efforts result in 
improved stroke patient care.47–50 This study, however, demonstrated that a state-based initiative 
based on the collaborative effort of professionals who are willing to share their expertise and 
exchange best practices results in tangible benefit to the community served. 
Patients treated at non-GCASR facilities continued to have the same hazard ratio 
throughout their follow-up time, indicating perhaps that the clinical care provided to patients at 
their first stroke episode influenced their risk of mortality in the subsequent years. Regardless of 
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whether hospitals participated in the GCASR, patient outcomes throughout Georgia improved 
with time. Compared with patients who had an acute ischemic stroke in 2009, patients during 
2006 through 2007 had a 9% higher risk of dying during the first year after the index admission. 
Development of new treatment guidelines and their implementation by health care providers may 
have contributed to the reduction in mortality; however, it is impossible to rule out a possible 
spillover effect of the GCASR initiatives to nonparticipating facilities. 
There was no meaningful difference in outcomes among hospitals of different size except 
for small hospitals (<100 beds) where patients had a 17% higher risk of mortality. Hospitals 
participating in GCASR tended to be metropolitan and larger, and although our analyses adjusted 
for these 2 variables, differences attributable to other variables between the 2 hospital groups 
cannot be ruled out. It is not possible, thus, to associate the reduction in hazard ratio among the 
GCASR hospitals entirely to the quality improvement initiatives undertaken by the registry. In 
future studies, linking the registry data (where interventions received by patients are 
documented) to the hospital discharge and death data will be helpful to associate the clinical care 
information with patient outcome. 
The yield from the linkage procedure was sufficient to assess the impact of the quality 
improvement program. There would be patients who died but were not picked by the matching 
procedure; however, failure to link was not related to the type of hospital where patients were 
treated in the test data set. Failure to link gives a lower estimate of the actual mortality but does 
not introduce bias in the study’s effect measure. Studies elsewhere reported different rates of 
mortality for ischemic stroke.51–55 The mortality at 1 month poststroke admission ranges from 
9% in Australian and Israeli studies to 17% in a Rochester, Minnesota, study. Also, the 1-year 
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mortality has been reported to vary from less than 10% in Japanese and Taiwanese studies to 
29% in the Minnesota study. The observed differences may be due to variations in study 
methodology, population characteristics, and quality of patient care. The 1-year mortality 
estimate observed in this analysis (18.5%) lies between extreme values that have been reported 
by other investigators, thus indicating that the linkage procedure was sufficiently sensitive and 
may even be a reasonable approach to estimate mortality and survival rates across the course of 
stroke patient care. We believe our estimates may be lower than expected rates because the data 
linkage may not have captured all patients who died in the given period, particularly those who 
died outside the state of Georgia. 
This study has limitations, some of which are inherent to any method that assesses the 
effect of a quality improvement intervention. It is difficult to define the time when the effect of 
such an intervention wanes, and several factors contribute to the overall well-being of a patient 
through time. Survival of acute ischemic stroke patients depends on factors such as patient and 
hospital characteristics, the time from symptom onset to arrival at the hospital, disease severity, 
the quality of service received from the health care facility on first encounter, the quality of 
rehabilitation services, and the quality of life once the patient is discharged from a hospital. This 
analysis took into account most of the prehospital discharge factors except for time elapsed 
between symptom onset and arrival at the hospital. In addition, we did not have information on 
postdischarge rehabilitation and quality of life. 
Although administrative data may lack consistent case definitions from one data set to 
another and the use of ICD-9 codes may not capture all possible acute stroke patients, the effect 
of misclassification is minimal in studies addressing the impact of hospitals’ participation in a 
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quality improvement registry, because misclassifications are more likely to be non-differential 
and would only reduce the effect measure toward the null value. Moreover, this study may not 
have completely captured disease severity, which is the main predictor of mortality. Different 
indices, including the National Institute of Health Stroke Scale, have been suggested by 
researchers to predict mortality, but there is no consensus index.56–60 Each one has its own merit 
in terms of feasibility of data collection, availability for data collection, and discriminatory 
power of fatal outcome. Several studies used the comorbidity measure, initially developed by 
Elixhauser et al44 in various disease conditions,61–66 and Zhu and Hill have demonstrated its 
usefulness in stroke as well.67. It is, thus, reasonable and practical to use comorbidity measures to 
account for disease severity. 
State-based hospital discharge data and death data can be linked and are excellent for 
estimating survival or risk for mortality, outcome measures that are helpful to assess the impact 
of clinical-level or community-level chronic disease control initiatives. The results of this study 
show that participation in a state-based stroke registry for improving the quality of care is 
associated with reduced mortality from acute ischemic stroke. Thus, hospitals should be 
encouraged either to participate in a structured program of quality improvement such as state-
based registries or undertake their own quality improvement to provide the best possible 
evidence-based care to their patients for a better outcome. 
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Table 1.  Algorithm for merging the Georgia Discharge Data System with the Georgia mortality data of 
the same calendar Year 
Linkage Step Linking Variable 
Distance Metric 
(Approve/Disapprove Level) 
Condition 
Weight,a% 
Acceptance 
Level,b% 
Step I 
LONGID
c
 Edit distance (0.05/0.15
d
) 70 
80 
Residence county Equal fields Boolean distance 15 
Race Equal fields Boolean distance 10 
Sex Equal fields Boolean distance 5 
Step II 
Name
e
 Edit distance (0.15/0.3) 40 
80 
Birth date Date distance (±0 d) 30 
Discharge date Date distance (±0 d) 20 
Residence zip code
f
 Equal fields Boolean distance 10 
Step III 
Name
e
 Edit distance (0.15/0.3) 40 
95 
Age, y Numeric distance (±0) 10 
Discharge date Date distance (±0 d) 20 
Residence zip code
f
 Equal fields Boolean distance 15 
Race Equal fields Boolean distance 10 
Sex Equal fields Boolean distance 5 
Step IV 
Birth date Date distance (±0 d) 35 
100 
Discharge date Date distance (±0 d) 25 
Residence county Equal fields Boolean distance 25 
Race Equal fields Boolean distance 10 
Sex Equal fields Boolean distance 5 
a: Proportional weight for each element in the linkage step. 
b: Total match score at which records are considered to be linked. 
c: 15-digit alphanumeric code created from letters of patients’ first and last names, birth date, and sex. 
d: The proportion of mismatched characters used to determine whether the records are considered to be linked. 
e: Refers to a 6-digit code derived from names. 
f: 5-digit zip code. 
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Table 2.  Algorithm for merging the Georgia Discharge Data System with the Georgia mortality data from 
different calendar years 
Linkage Step Linking Variable 
Distance Metric 
(Approve/Disapprove Level) 
Condition 
Weight,a% 
Acceptance 
Level,b% 
Step I 
LONGIDc Edit distance (0.05/0.15) 70 
80 
Residence county Equal fields Boolean distance 15 
Race Equal fields Boolean distance 10 
Sex Equal fields Boolean distance 5 
Step II 
Named Equal fields Boolean distance 40 
81 
Birth date Date distance (±0 d) 30 
Residence zip codee Equal fields Boolean distance 15 
Race Equal fields Boolean distance 10 
Sex Equal fields Boolean distance 5 
Step III 
Named Edit distance (0.15/0.3) 40 
100 
Age Numeric distance (±0) 30 
Residence county Equal fields Boolean distance 15 
Race Equal fields Boolean distance 10 
Sex Equal fields Boolean distance 5 
a: Proportional weight for each element in the linkage step. 
b: Total of condition weights at which records are considered to be linked. 
c: 15-digit alphanumeric code created from letters of patients’ first and last names, birth date, and sex. 
d: Refers to a 6-digit code derived from names. 
e: 5-digit zip code. 
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Table 3.  Agreement in the matching variables of the linked Georgia hospital discharge data and Georgia 
mortality data 
Variable 
Agreement, % 
Test Data and 2006 
Death Data 
2006–2009 Hospital 
Discharge and 2006–
2010 Death Data 
LONGIDa 85.8 91.3 
Birth date 94.5 96.2 
Nameb 91.9 98.3 
Sex 99.2 99.8 
Age 98.1 —d 
Race 95.2 96.8 
Residence county 91.0 88.3 
Residence zip codec 62.0 62.6 
Facility 93.6 —d 
Discharge date or date of death 92.6 —d 
a: 15-digit alphanumeric code created from letters of patients’ first and last names, birth date, and sex. 
b: Refers to a 6-digit code derived from names. 
c: 5-digit zip code. 
d: Not all records are expected to match. 
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Table 4.  Characteristics of acute ischemic stroke patients (n = 50,579) cared for by Georgia Coverdell 
Acute Stroke Registry participating and nonparticipating hospitals, Georgia Hospital Discharge 
Data, 2006–2009, and Georgia Mortality Data, 2006–2010 
Characteristics 
Treatment Location 
P-Valueb 
All Hospitals 
GCASR 
Hospitals 
Non-GCASR 
Hospitalsa 
Age, y, mean (SD) 68.7 (13.9) 68.2 (13.9) 69.3 (13.9) .12 
Sex, n (%) 
 Male 
 Female 
 
24,494 (48.4) 
26,085 (51.6) 
 
13,948 (49.7) 
14,129 (50.3) 
 
10,546 (46.9) 
11,956 (53.1) 
<.001 
Race, n (%) 
 White 
 Black 
 Other 
 
33,619 (66.5) 
15,695 (31.0) 
1,265 (2.5) 
 
18,813 (67.0) 
8,445 (30.1) 
819 (2.9) 
 
14,806 (65.8) 
7,250 (32.2) 
446 (2.0) 
.63 
Primary insurance coverage, n (%) 
 Medicare 
 Medicaid 
 Private 
 Self-pay 
 All others 
 
32,438 (64.1) 
2,877 (5.7) 
10,329 (20.4) 
3,607 (7.1) 
1,328 (2.6) 
 
17,531 (62.4) 
1,687 (6.0) 
6,088 (21.7) 
2,097 (7.5) 
674 (2.4) 
 
14,907 (66.3) 
1,190 (5.3) 
4,241 (18.8) 
1,510 (6.7) 
654 (2.9) 
.31 
Length of stay, d, median (interquartile range) 3.0 (2–6) 2.8 (1.3–5.4) 3.2 (1.7–5.6) .80 
Hospital size, n (%) 
 <100 beds 
 100–249 beds 
 250–399 beds 
 ≥400 beds 
 
70 (53.4) 
29 (22.1) 
15 (11.5) 
17 (13.0) 
 
22 (36.7) 
11 (18.3) 
12 (20.0) 
15 (25.0) 
 
48 (67.6) 
18 (25.4) 
3 (4.2) 
2 (2.8) 
<.001 
Hospital location, n (%)
c
 
 Metropolitan 
 Nonmetropolitan 
62 (47.3) 
69 (52.7) 
40 (66.7) 
20 (33.3) 
22 (31.0) 
49 (69.0) 
<.001 
Calendar year, n (%) 
 2006 
 2007 
 2008 
 2009 
 
12,331 (24.4) 
12,959 (25.6) 
12,849 (25.4) 
12,440 (24.6) 
 
4,743 (16.9) 
7,175 (25.5) 
7,972 (28.4) 
8,187 (29.2) 
 
7,588 (33.7) 
5,784 (25.7) 
4,877 (21.7) 
4,253 (18.9) 
<.001 
No. (%) of deaths  
 Discharge 
 30 days 
 365 days 
 End of follow-up 
 
1,940 (3.8) 
4,114 (8.1) 
9,350 (18.5) 
14,699 (29.1) 
 
1,000 (3.6) 
2,105 (7.5) 
4,740 (16.9) 
7,281 (25.9) 
 
940 (4.2) 
2,009 (8.9) 
4,610 (20.5) 
7,418 (33.0) 
 
.08 
<.001 
<.001 
<.001 
Abbreviation: GCASR, Georgia Coverdell Acute Stroke Registry; SD, standard deviation. 
a: Non-GCASR hospitals are those that never participated in GCASR from 2006 through 2009. 
b: χ2 and Wilcoxon tests were applied for nominal and quantitative variables, respectively. 
c: Based on Rural-Urban Commuting Area classification of location to classify hospitals geographically as metropolitan (codes 1–
3) or nonmetropolitan (codes >3)7.  
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Table 5.  Relative risk for death for Georgians with acute ischemic stroke, Georgia Hospital Discharge 
Data, 2006–2009, and Georgia Mortality Data, 2006–2010 
Characteristic 
Hazard Ratioa in the First Year Post Stroke Admission 
Estimate (95% CI) P-Valueb 
Location of treatment  
 Hospital not participating in GCASR 
 Hospital participating in GCASR 
 
1.14 (1.03–1.26) 
1 [Reference] 
.01 
Sex  
 Male 
 Female 
0.93 (0.89–0.98) 
1 [Reference] 
.004 
Age group, y  
 ≥80 
 65–79 
 45–64 
 <45 
 
5.45 (4.53–6.56) 
2.18 (1.83–2.62) 
1.34 (1.14–1.57) 
1 [Reference] 
 
<.001 
<.001 
<.001 
 
Race  
 Other 
 White 
 
1.03 (0.96–1.11) 
1 [Reference] 
 
.36 
 
Primary insurance coverage  
 Medicaid 
 Private 
 Self-pay 
 All others 
 Medicare 
 
1.06 (0.94–1.19) 
0.75 (0.67–0.84) 
0.62 (0.51–0.75) 
0.91 (0.80–1.19) 
1 [Reference] 
 
.35 
<.001 
<.001 
.84 
 
Length of stay, d 1.017 (1.013–1.022) <.001 
Hospital size, n (%) 
 <100 beds 
 100–249 beds 
 250–399 beds 
 ≥400 beds 
 
1.17 (1.02–1.33) 
1.04 (0.92–1.18) 
1.05 (0.91–1.21) 
1 [Reference] 
 
.02 
.54 
.48 
 
Hospital location
c
 
 Nonmetropolitan 
 Metropolitan 
 
1.11 (1.03–1.21) 
1 [Reference] 
.009 
Calendar year 
 2006 
 2007 
 2008 
 2009 
 
1.09 (1.02–1.18) 
1.09 (1.02–1.17) 
1.02 (0.95–1.09) 
1 [Reference] 
 
.02 
.007 
.64 
 
Abbreviation: CI, confidence interval; GCASR, Georgia Coverdell Acute Stroke Registry. 
a: Adjusted for comorbidities. 
b: χ2 and Wilcoxon tests were applied for nominal and quantitative variables, respectively. 
c: Based on Rural-Urban Commuting Area classification of location to classify hospitals geographically as metropolitan (codes 1–
3) or nonmetropolitan (codes >3).7 
 
  
27 
 
CHAPTER III 
Quality of Care and Its Impact on One Year Mortality: the Georgia Coverdell Acute 
Stroke Registry 
Abstract 
Introduction 
Although performance measures to monitor the quality of acute stroke care exist, their 
utility in measuring long-term outcomes is uncertain. This study assessed the 1-year mortality of 
acute ischemic stroke patients cared for by hospitals participating in the Georgia Coverdell Acute 
Stroke Registry. 
Methods 
The 2008-2013 Georgia Coverdell Acute Stroke Registry data were linked with hospital 
discharge and death data using both hierarchical deterministic and probabilistic linkage 
procedures. Delivery of care components related to ten nationally-approved performance 
measures were used to define whether patients received quality care. Defect-free care and 
composite measure methods were used to measure the quality of care. A generalized estimating 
equation was applied, accounting for correlation at hospital level and taking hospital as a random 
variable to assess the effect of quality of care on 1-year mortality. 
Results 
“Defect-free care” was positively associated with increased mortality; however, it was 
also associated positively with stroke severity. The composite measure showed that patients who 
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received the lowest and intermediate quality care, respectively, had a 3.94 (95%CI: 3.27, 4.75; p-
value <0.0001) and a 1.38 (95%CI: 1.12, 1.62; p-value=0.002) times higher odds of dying in one 
year compared to those who got the best quality stroke care. 
Conclusion 
Data from the Georgia Coverdell Acute Stroke registry suggest that the defect-free care 
measure is not helpful in assessing the impact of quality improvement activities. However, the 
composite measure indicated that hospitals should be encouraged to implement quality 
improvement activities for better long-term stroke patient outcome. 
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INTRODUCTION 
A wealth of scientific evidence shows that improvement in specific elements of clinical 
stroke care could result in better patient outcomes.33 The Centers for Disease Control and 
Prevention (CDC), the American Heart Association, and the Joint Commission have identified 
ten specific elements of clinical care and developed associated indicators (Table 6) to measure 
the quality of stroke care.32,33 Not every component of stroke care is indicated for all stroke 
patients; rather, patients receive care based on their specific needs. A patient who received all 
indicated care components is said to have had a “defect-free care,” an indicator that helps to 
monitor progress in the quality of stroke care delivery. 
The Georgia Coverdell Acute Stroke Registry (GCASR) was established by the Georgia 
Department of Public Health, in collaboration with its partners and funded by CDC, to measure, 
monitor, and improve the quality of acute stroke care across the state. Hospitals participating in 
GCASR have shown significant improvement in the process of stroke patient care and delivery 
of defect-free care.34,36 Nevertheless, improvement in the process of care delivery may not 
necessarily translate into improvement in patient outcomes.24-26 Hence, the objective of this study 
was to assess whether quality improvement as measured by defect-free care or a composite 
measure is associated with improved short- and long-term outcomes among acute ischemic 
stroke patients. 
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METHODS 
Data Sources and Linkage 
This is a retrospective cohort study of acute ischemic stroke patients cared for by 
GCASR-participating hospitals during 2008-2013. We used three data sources – the GCASR 
data, the Georgia Discharge Data System (GDDS) and the Georgia death data. We linked the 
GCASR and GDDS data using a hierarchical deterministic linkage procedure (sensitivity 87% 
and positive predictive value 96%); the output was then linked with the death data applying a 
probabilistic linkage approach (sensitivity 92% and specificity 100%). The probabilistic linkage 
procedure and its yield is described previously68, and details on the deterministic linkage 
procedure are provided as Annex. The Fine-Grained Record Integration and Linkage software 
program version 2.1.5 was used to link the three data sources were linked stepwise using.42 
Patients from the stroke registry with clinical diagnosis of acute ischemic stroke in 2008–
2013 were included in this study. We had 45,727 records with a clinical diagnosis of acute 
ischemic stroke in the initial GCASR data list. Of these, 41,216 were linked with GDDS data but 
only 39,331 had the data element critical for linking with the death data. Excluding the 
readmissions, we had 36,043 subjects eligible for follow-up, and 35,028 were eligible for, at 
least, one evidence-based stroke care component. We excluded from the analysis patients with 
undocumented time of symptom onset because 59% of the observations have missing value 
(Figure 1). 
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Defect-free Care Measure 
Patients were classified as having had a defect-free care if they received all elements for 
which they were eligible as specified by the ten performance measures (Table 6). Defect-free 
care does not take into account the number of care components patients are eligible to receive. 
Thus, a patient who is eligible for three care components and received all is declared as having 
had a defect-free care while a patient who received seven out of eight indicated care components 
is identified as not having had a defect-free care. 
Composite Measure 
A composite measure, taking the proportion of indicated care components a patient 
received, is an alternative measure of quality of care.47,69 However, it doesn’t fully account for 
the number of indicated care components because delivery of eight out of eight would have the 
same composite measure of 100% as providing three out of three. Thus, we weighted the 
composite measure by the natural logarithm of the total number of indicated care components. 
The care requiring eight elements will have a higher weight [ln(8)=2.0794] than the one with 
three indicated care components [ln(3)=1.0986]. Patients were grouped in tertiles based on their 
weighted composite measures. Those in the 1st terile with the lowest weighted composite 
measure were considered to have had, relatively, the lowest quality of care; those in the 2nd tertile 
represented an intermediate and patients in the 3rd tertile represented the best quality of stroke 
care. 
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Statistical Analyses 
All analyses were done using SAS version 9.3 (SAS Institute, Inc., Cary, NC). Quality 
of stroke care as measured by defect-free care or the composite indicator was the main predictor 
of outcome. Death from any cause within 365 days from index admission and ambulatory status 
at discharge were the outcomes of interest. We classified ambulatory status at discharge into two 
groups: unable to walk, and walking with or without assistance from another person. Those who 
were not ambulating independently before the stroke event were excluded from the analysis. 
Patient’s characteristics such as age, gender, race and insurance status, National Institute 
of Health (NIH) stroke scale score, presence of persistent atrial fibrillation or flutter, previous 
medical and medication history and nothing per mouth status; event-related characteristics such 
as symptom onset to hospital arrival time, day, time and year of admission; and hospital features 
including number of beds and location were considered as covariates in the analysis. Based on 
their distribution on the basis of number of beds, hospitals were classified as small (<100 beds), 
medium-small (100–249 beds), medium-large (250–399 beds) and large hospitals (≥400 beds). 
We used the Rural-Urban Commuting Area classification (version 2.0) of location to classify 
hospitals geographically into metropolitan (codes 1–3) and nonmetropolitan (codes >3).43 We 
assessed patient, hospital and event related characteristics descriptively and tested for differences 
between patients who did and did not receive defect-free care using χ2 tests for nominal variables 
and Wilcoxon tests for quantitative variables. 
Data elements included in the multivariable analyses had missing values in less than 5% 
of the observations except for NIH stroke scale which has missing values for 29% of the 
observations, respectively. Therefore, we performed multiple imputation with 20 replications 
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assuming a general missing pattern and missing at random on data elements included in the 
analysis.70 We applied generalized estimating equations (GLIMMIX procedure) to assess the 
outcomes controlling for in-hospital correlation and considering hospital as a random variable. 
RESULTS 
Among the 14,246 acute ischemic stroke patients included in the study, 51.3% were 
female, 61.8% were White, and the median age was 69 years (IQR: 58, 80). The three most 
common comorbidities were hypertension (82.4%), dyslipidemia (41.1%) and diabetes mellitus 
(34.5%). Based on the ten performance measures, 69.1% received defect-free care and on 
aggregate patients received 92.8% of the indicated care components. Patients who received 
defect-free care had more severe stroke than their counterparts; a relatively higher proportion of 
them were also non-ambulating at discharge and died within one year of the incident (Table 7). 
Patients with more number of indicated care components were less likely to receive 
defect-free care (Figure 2) than those with relatively fewer indicated elements of stroke care. 
Moreover, stroke was more severe among patients with fewer indicated care components (Figure 
3). Patients with three or fewer indicated care components had a 72.9% 1-year mortality while 
those with more than three had a 12.4% 1-year mortality. 
The 1-year mortality among patients with a missing value in a predictor variable was 
19.1% compared to the 19.7% among those with complete data. On multivariate analyses of the 
imputed data, patients who did not receive defect-free care had a 0.87 (95%CI: 0.75, 1.00; p-
value=0.05) lower odds of dying in one year compared to those who received defect-free care. 
Moreover, they also had a 0.58 (95%CI: 0.48, 0.67; p-value<0.0001) lower odds of not 
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ambulating at discharge. Nonetheless, when quality of stroke care was measured by the 
composite indicator, those who received the lowest and intermediate quality of care had higher 
odds (OR=3.94; 95%CI: 3.27, 4.75; p-value <0.0001 and OR=1.35; 95%CI: 1.12, 1.62; p-
value=0.002, respectively) of dying within one year compared to those who received the best 
quality stroke care. Furthermore, patients with the lowest and intermediate quality care had 
statistically significant 5.7 times (95%CI: 4.59, 7.06; p-value<0.0001) and 3.08 (95%CI: 2.53, 
3.75; p-value<0.0001) greater odds, respectively, of not ambulating at discharge compared to 
their counterparts. (Table 8). Similar results were also documented on complete data analysis. 
DISCUSSION 
The result of this study shows that acute ischemic stroke patients who received a quality 
care had a better long-term outcome. The odds for dying within one year increased progressively 
as the quality of care patients received diminished. Similarly, a statistically significant positive 
association was documented between the quality of stroke care and patients’ ambulatory status at 
discharge. 
Contrary to what is expected, patients who did not receive better care, as measured by 
defect-free care, appeared to have better outcomes. They had a 13% and a 42% lower odds of 
dying in the first year and non-ambulating at discharge, respectively, compared to those who 
received defect-free care. Our analysis further revealed that patients with more severe stroke 
were eligible to receive fewer number of care components and were more likely to have defect-
free care. Although we adjusted for measures of disease acuity, including the NIH stroke scale 
score, we cannot vouch that severity is captured fully by the score. 
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Compared to the all-or-none scoring of defect-free care, the composite measure captured 
intermediate level care quality and gave credit for delivery of some, not necessarily all, of the 
indicated care processes. It gave equal weight to each care component and presented quality of 
care on a continuous scale rather than as a binary outcome. The impact of each care element on 
patient outcome, however, may be different and this may require assigning different weights. 
This study has some methodological limitations. Fourteen percent of the initial study 
subject were excluded because they did not match records from the hospital discharge data. 
Obviously this could introduce bias, namely a non-differential bias because record matching was 
not related to the quality of care patients received. Patient without documented symptom onset 
time were also excluded, and we imputed for missing values, mainly for NIH stroke scale score, 
for a third of the study subjects. This may introduce bias as well; however, the 1-year mortality 
weren’t different between patients with and without complete data. Despite these limitations, our 
findings were also similar in both the complete and imputed data analyses, indicating that the 
bias would only be minimal. 
Measuring quality of care is an arduous exercise and requires rigorous examination of 
what each measure entails. It involves identifying care components that would have effect on 
patient outcome, defining the subset of patient groups who would be eligible, establishing 
procedures for delivery and documentation of the care component and determining whether an 
eligible patient received the care indicated. It is possible that errors could be introduced at any 
step of assessing the quality of care delivery. The error gets compounded when measures of 
several quality of care components are aggregated in an all-or-none fashion as in defect-free 
care. The composite measure, on the other hand, was not influenced by the number of care 
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components indicated for a patient. Error in measurement of one care component could affect 
partly the aggregate measure of quality of care. Thus, defect-free care, though a stringent 
aggregate indicator for monitoring and improving the process of care delivery, is not the ideal 
quality measure when the impact of quality improvement initiatives in stroke care is evaluated. 
Although each component of stroke care is backed by scientific evidences,33 it is 
important to evaluate their effectiveness in the aggregate, in the context of a quality 
improvement initiative. To the best of our knowledge, no study has examined the long-term 
effects of hospital-based quality improvement initiative in stroke care. This study assessed both 
short and long-term outcomes and showed that patients who received better care had a lower risk 
of death, a finding which could expand quality improvement activities across hospitals caring for 
stroke patients. 
Conclusion 
Quality improvement initiatives improve not only the process of care delivery but also 
patient outcome. Hospitals should be encouraged to undertake quality improvement activities to 
measure and monitor the nationally recommended performance indicators in order to improve 
the quality of their stroke patient care. 
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Table 6.  Performance measures endorsed by the CDC, the American Heart Association/American 
Stroke Association and the Joint Commission 
Performance measures 
Venous thromboembolism prophylaxis 
Administration of antithrombotic medication within 48 hours 
Anticoagulant medication for patients with atrial fibrillation 
Administration of tissue plasminogen activator (tPA) 
Dysphagia screening 
Antithrombotic medication at discharge 
Prescription of lipid lowering medication 
Stroke education 
Smoking cessation counseling or treatment 
Rehabilitation assessment 
Source: MMWR Morb Mortal Wkly Rep. 2011;60(7):206-10. 
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Table 7.  Characteristics of acute ischemic patients by defect-free care status, Georgia Coverdell Acute 
Stroke Registry, 2008–2013 
Characteristics Total 
Patient Did 
Not Receive 
DFCa 
Patient 
Received 
DFCa 
P-valueb 
Age, median (IQR) 69 (58, 80) 68 (57, 79) 69 (58. 80) <.0001 
Female, n(%) 7,309 (51.3) 2,291 (52.1) 5,018 (51.0) 0.20 
Whites, n(%) 8,808 (61.8) 2,828 (64.30) 5,980 (60.7) <.0001 
Medicare health insurance coverage, n(%) 8,497 (59.7) 2,552 (58.1) 5,945 (60.4) 0.01 
NIH stroke scale score (unit), median (IQR) 6 (2, 13) 4 (1, 9) 6 (2, 14) <.0001 
Atrial fibrillation/flutter, n(%) 2,936 (20.6) 796 (18.1) 2,140 (21.7) <.0001 
Nothing per mouth, n(%) 1,323 (9.3) 232 (5.3) 1,091 (11.1) <.0001 
Last known well to hospital arrival time 
(minutes), median(IQR) 
183 (69, 460) 158 (66, 399) 195 (71, 480) <.0001 
Hospital bed size, n(%) 
 <100 beds 
 100–249 beds 
 250–399 beds 
 >=400 beds 
 
483 (3.4) 
2,378 (16.7) 
3,424 (24.0) 
7,961 (55.9) 
 
307 (7.0) 
884(20.1) 
1,005 (22.9) 
2,200 (50.0) 
 
176 (1.8) 
1,494 (15.2) 
2,419 (24.6) 
5,761 (58.5) 
<.0001 
Day of the week,c n(%) 
 Week day 
 Weekend 
 
10,018 (71.7) 
3,958 (28.3) 
 
3,191 (72.6) 
1,205 (27.4) 
 
7,097 (72.1) 
2,753 (27.9) 
0.51 
Hour of the day,c n(%) 
 Night 
 Day 
 
5,217 (36.6) 
9,029 (63.4) 
 
1,600 (36.4) 
2,796 (63.6) 
 
3,617 (36.7) 
6,233 (63.3) 
0.71 
Calendar year, n(%) 
 2008 
 2009 
 2010 
 2011 
 2012 
 2013 
 
1,419 (10.0) 
1,656 (11.6) 
2,231 (15.7) 
2,617 (18.4) 
3,088 (21.7) 
3,235 (22.7) 
 
911 (20.7) 
873 (19.9) 
600 (13.6) 
651 (14.8) 
702 (16.0) 
659 (15.0) 
 
508 (5.2) 
783 (7.9) 
1,631 (16.6) 
1,966 (20.0) 
2,386 (24.2) 
2,576 (26.2) 
<.0001 
Outcome, n(%) 
 Death in 1-Year 
 Not ambulating at discharged 
 
2,775 (19.5) 
1,594 (14.0) 
 
672 (15.3) 
303 (8.5) 
 
2,103 (21.4) 
1,291 (16.5) 
 
<.0001 
<.0001 
Note:-  IQR = Interquartile range; DFC = Defect-free care 
a: Defect-free care: delivery of care meeting all quality indicators for which a patient is eligible 
b: chi-square and Wilcoxon tests were applied for nominal and quantitative variables, respectively. 
c: refers to the admission day and time 
d: among patients who were ambulating prior to the stroke incident 
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Table 8.  Relative risk of 1-year mortality and non-ambulating at discharge among acute ischemic stroke 
patients by quality of care, Georgia Coverdell Acute Stroke Registry 2008-2013. 
Performance 
measure 
Complete Data Imputed Data 
Death in one year post 
incident 
Not Ambulating at 
Dischargea 
Death in one year post 
incident 
Not Ambulating at 
Dischargea 
Odds Ratio 
(95%CI) 
P-value 
Odds Ratio 
(95%CI) 
P-value 
Odds Ratio 
(95%CI) 
P-value 
Odds Ratio 
(95%CI) 
P-value 
Received defect-free 
careb 
 No 
 
 Yes 
 
 
0.84 
(0.69, 1.02) 
Referent 
0.073 
 
 
0.67 
(0.54, 0.82) 
Referent 
0.0003 
 
 
0.87 
(0.75, 1.00) 
Referent 
0.05 
 
 
0.58 
(0.48, 0.67) 
Referent 
<0.0001 
Weighted Composite 
Indexc 
 1st Tertile 
 
 2nd Tertile 
 
 3rd Tertile 
 
 
4.10 
(3.27, 5.13) 
1.28 
(1.02, 1.60) 
Referent 
<0.0001 
 
 
6.64 
(5.09, 8.66) 
3.06 
(2.41, 3.89) 
Referent 
<0.0001 
 
 
3.94 
(3.27, 4.75) 
1.35 
(1.12, 1.62) 
Referent 
 
 
 
<0.0001 
 
0.002 
 
 
 
5.70 
(4.59, 7.06) 
3.08 
(2.53, 3.75) 
Referent 
 
 
 
<0.0001 
 
<0.0001 
 
Note:-  the estimates are adjusted for age, gender, race and insurance status, National Institute of Health stroke scale score, 
presence of persistent atrial fibrillation or flutter, previous medical and medication history and nothing per mouth 
status, symptom onset to hospital arrival time, time, day year of admission, hospital number of beds and location. 
a:  among patients who were ambulating on prior to the stroke incident 
b:  a patient who received all the indicated care components related to the ten performance measures is labelled to have 
had a defect-free care 
c: proportion of performance measures weighted by natural logarithm of the total number of indicated care 
components; the quality of care improves going from the first to the third tertile 
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Figure 1. Flow diagram for patients included in the analysis 
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Figure 2.  Defect-free care and average composite measure by the number of performance measure acute 
ischemic patients were eligible for, Georgia Coverdell Acute Stroke Registry, 2008-2013 
(DFC (defect-free care):  when a patient received all the care components related to the ten performance 
measures that are indicated 
Composite:   the percentage of indicated performance measures a patient received) 
 
 
 
Figure 3.  Median National Institute of Health stroke scale score by the number of performance measure 
acute ischemic patients were eligible for, Georgia Coverdell Acute Stroke Registry, 2008-2013 
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CHAPTER IV 
The Impact of Intravenous Alteplase on Long-term Patient Survival: the Georgia 
Coverdell Acute Stroke Registry’s Experience 
Abstract 
Introduction 
Intravenous alteplase reduces disability and improves functionality among acute ischemic 
stroke patients. Two decades after its approval, only a small fraction of patients get the treatment, 
and demonstrating its impact on mortality may make a strong case for its wider use. This study 
assessed the impact of thrombolytic treatment by alteplase on 1-year mortality and readmission 
among acute ischemic stroke patients. 
Method 
The 2008-2013 Georgia Coverdell Acute Stroke Registry data were linked with the 2008-
2013 hospital discharge and the 2008-2014 death data in Georgia. Multiple imputation was 
applied; a propensity score measuring the probability of receiving intravenous alteplase was 
calculated and used for matching. A conditional logistic regression was applied to compare 1-
year mortality and readmission among propensity score matched pairs. 
Results 
Overall, 20.3% of 9,620 acute ischemic stroke patients died and 22.4% were readmitted 
in one year. The multivariable regression result showed that patients who did not receive IV 
alteplase had a 1.49 (95%CI: 1.09-2.04; p-value=0.01) times higher odds of dying at one year 
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than those who were treated with the thrombolytic agent. Among patients discharged home, no 
statistically significant difference was documented in the odds of being readmitted at least once 
within 365 days post-stroke discharge. 
Discussion and Conclusion 
The benefits of intravenous alteplase are not limited to improvement in function or 
absence of disability but also in reduction of mortality. The results of this study suggests that 
patients who are identified as eligible for intravenous alteplase need to be offered the treatment.  
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INTRODUCTION 
Intravenous alteplase was approved in 1996 by FDA as a thrombolytic agent in ischemic 
stroke because patients who received the treatment are 30% more likely to have minimal or no 
disability at three month after the index incident71 and one year after the index incident.72 Twenty 
years later, fewer than 10% of ischemic stroke patients receive the treatment.73,74 Delay in stroke 
identification, lack of swift transport to stroke ready facilities, contraindications and warning 
symptoms, and indecision to provide intravenous (IV) alteplase by healthcare providers,75,76 may 
be associated with low rates of alteplase use. 
Demonstration of IV alteplase’s impact on long-term mortality rather than on disability 
could make a strong case for its wider use. To date, the few studies designed to assess patient 
outcome using mortality have not shown positive results, possibly because of shorter duration of 
follow-ups, differential effect of IV alteplase based on stroke severity, and small sample 
size.72,77-79 Stroke registries help to monitor and measure patient outcomes in the long-term and 
provide data to support the needed research.80 This study is conducted to evaluate the impact of 
receiving intravenous thrombolytic treatment on 1-year mortality of stroke patients cared for by 
hospitals participating in the Georgia Coverdell Acute Stroke Registry. 
METHODS 
We conducted a passive follow-up of acute ischemic stroke patients cared for by 
hospitals participating in the Georgia Coverdell Acute Stroke Registry (GCASR). The Georgia 
Coverdell Acute Stroke Registry is part of the National Paul Coverdell Acute Stroke Program 
and is designed to monitor the quality of stroke care in the state.32 The registry has the goal of 
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reducing stroke disability, premature mortality and preventing recurrent stroke through 
improvement in quality of stroke care in collaboration with the participating hospitals and other 
stakeholders. 
Data Sources and data linkage 
We used the 2008-2013 GCASR data, the 2008-2013 Georgia Discharge Data System 
(GDDS) and the 2008-2014 Georgia death data for this study. The GDDS has information on 
patients discharged from non-federal acute care hospitals in Georgia. The death data are 
collected from death certificates and provide information on deaths of Georgians including those 
who passed away in other states. The three data sources were linked stepwise using the Fine-
Grained Record Integration and Linkage software program version 2.1.5.42 First, we linked the 
GCASR data with GDDS data using a hierarchical deterministic procedure; the output was, 
subsequently, linked with the death data using a probabilistic data linkage approach. We used 
hospital code, admission and discharge date, age, race and gender for matching the GCASR data 
with GDDS data. Additional information on residence (ZIP code and county) and a 15 digit 
alphanumerical code – composed of the first two letters of the first name, the first and last two 
letters of last name, birthdate and gender – were added for the probabilistic linkage. 
Similar to a previous study, in which the probabilistic linkage between hospital discharge 
and death data was seen to have a very good accuracy with 92% sensitivity and 100% 
specificity,68 the deterministic linkage in this study had a sensitivity of 87% and positive 
predictive value of 96% (details provided as Annex). There were 45,727 records with a clinical 
diagnosis of acute ischemic stroke in the initial GCASR data list. Of these, 41,216 were linked 
with GDDS data but only 39,331 had LONGID, the data element critical for linking with the 
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death data and for determining readmissions from index admission. After excluding the 
readmissions, 36,043 subjects were eligible for follow-up (Figure 4). 
Inclusion and Exclusion Criteria 
In this study, we included only subjects who were eligible for IV alteplase administration. 
Based on AHA’s guidelines for the early management of patients with acute ischemic stroke,81 
patients with contraindications and warning symptoms and those with spontaneous stroke 
symptom recovery or a National Institute of Health (NIH) stroke scale score of zero were 
considered ineligible for IV alteplase. We excluded from analysis patients with in-hospital 
stroke, symptom onset (last known to be well) to hospital arrival time greater than 270 minutes 
or no symptom onset time documented and patients from hospitals with no IV alteplase treated 
patients during the study period. 
Statistical Analysis 
The main outcome of interest was death from any cause within 365 days after index 
patients’ admission. Readmission for any cause within 365 days post discharge among patients 
discharged home was also assessed as a secondary outcome. Treatment with IV alteplase 
documented in the registry was the main predictor of outcome. 
Data elements included in the analyses had missing values in less than 5% of the 
observations except for NIH stroke scale which had 29% missing values. Altogether, 38% of the 
observations had missing value at least for one variable. Therefore, we performed multiple 
imputation on 9,620 observations assuming a general missing pattern and missing at random 
with twenty replications on variables considered to have relation with receiving IV alteplase and 
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patient’s outcome.70 To assess for bias from imputation, we analyzed the data with complete 
information as well. 
A propensity score measuring the probability of receiving IV alteplase was calculated 
using variables that could be related to the decision of administering thrombolytic. Age, gender, 
race, Medicare as major source of health insurance, transport to hospital by EMS, last known 
well to hospital arrival time, history of other illnesses and medication, severity of patient 
condition as documented by NIH stroke scale score and nothing per mouth status, hospital bed 
size, hour, day and year of admission were treated as predictors. Hospital bed size and NIH 
Stroke Scale score were categorized based on their distribution; hospital bed size was classified 
as small (<100 beds), medium-small (101-249 beds), medium-large (250-400 beds) and large 
(>400 beds) while the NIH Stroke Score was classified in quartiles (0-4, 5-8, 9-14, and greater 
than 14). Hospitals were classified geographically as metropolitan (codes 1-3) and non-
metropolitan (codes >3) based on the Rural-Urban Commuting Area classification (version2.0) 
of location.43 
We used the propensity score for variable reduction and matching.82 Patients treated with 
IV alteplase were matched one-to one with those eligible but didn’t receive the treatment using a 
SAS macro program.83 Alteplase treated patients were first matched to controls on 8 digits of the 
propensity score. Those that did not match were then matched to controls on 7 digits of the score, 
and we continued the matching down to a 1-digit match. The average difference in propensity 
score between the matched pairs was less than 0.001. 
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We compared the characteristics of IV alteplase treated and non-treated patients, among 
those eligible for the thrombolytic medication and with complete information, using chi-square 
test for categorical variables and Wilcoxon test for continuous variables. We compared 
outcomes, on imputed data, among propensity score matched pairs using conditional logistic 
regression. The analyses were done using the SAS® statistical software version 9.3 (SAS 
Institute, Inc.). 
RESULTS 
The final analytical dataset had 9,620 patients from 48 hospitals with a median age of 68 
years (IQR: 57, 80 years). More than half (52%) were female, 60% were white, 59% had 
Medicare as their main source of health insurance coverage, and 25.8% received IV alteplase. 
The average overall mortality rates documented were 4.6% at 7 days, 10.4% at 30 days, 13.5% at 
90 days and 20.3% at one year. Moreover, 22.4% of the patients were readmitted within one year 
post discharge. Based on information from patients with complete data (n=2,925), patients 
treated with IV alteplase had statistically significantly different features including age, health 
insurance coverage, means of transport to hospital, NIH stroke scale score, NPO status and 
medication intake prior to admission compared to those who were eligible but didn’t receive the 
treatment (Table 9). 
The one year mortality among patients with a missing value in a predictor variable was 
20.5% compared to the 22.3% among those with complete data. The aggregate conditional 
logistic regression result from imputed data showed that patients who did not receive IV 
alteplase had a 1.49 (95%CI: 1.09-2.04; p-value=0.01) times higher odds of dying at one year 
than those who were treated with the thrombolytic agent (Table 10). The lowest and highest odds 
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ratios observed in the twenty replicates were 1.22 and 1.70, respectively. Moreover, the analysis 
on complete records (n=348 pairs) showed a result in similar direction albeit statistically not as 
significant (p-value=0.37) as the one on imputed data (Table 10). Among patients discharged 
home, no statistically significant difference (OR=0.90, 95%CI: 0.59, 1.39, p-value=0.24) was 
documented in the odds of being readmitted at least once within 365 days post discharge (Table 
2). 
DISCUSSION 
Acute ischemic stroke patients who were treated with intravenous thrombolysis had a 
better odds of survival at one year post discharge. Those who were eligible but didn’t receive 
intravenous alteplase had a 49% higher odds of dying at one year than those who received the 
thrombolytic agent. The data, however, didn’t show evidence that intravenous thrombolysis 
reduces 1-year readmission among patients discharged home. 
Prior studies with randomized design haven’t shown a statistically significant reduction 
of 1-year mortality for patients treated IV alteplase.72,77-79 The observed difference might be due 
to differences in characteristics of study populations. The NINDS study72 applied exclusion 
criteria similar to those used in this study, but it included only patients who could be treated 
within 3 hours of symptom onset. The third International Stroke Trial (IST) study,77 on the other 
hand, included patients who neither had a clear indication nor contraindication for IV alteplase 
and who could be treated within 6 hours of symptom onset. 
Administration of IV alteplase has its own risk for complication such as bleeding and is 
not indicated for all patients who present with acute ischemic stroke. In this study, we considered 
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only patients who do not have a condition that may preclude the use of IV alteplase. In a similar 
observational study,80 where only eligible patients as defined by national guidelines were 
considered, Schmitz et al. reported a similar finding (Hazard Ratio = 1.52; 95% confidence 
interval, 1.14–2.04) based on the Danish Stroke Registry. 
Some shortcomings are worth considering in the interpretation of the result of this study. 
One, aside from the clinical diagnosis, no imaging information was available to differentiate the 
type and extent of ischemic insult that may affect patient outcome.84 Two, the data linkage left 
out 14% unmatched patient records and could potentially introduce bias. Three, we applied 
multiple imputation to get accurate estimates that are generalizable to the study population. 
Patients with missing data had a 1-year mortality (20.5%) comparable to those with complete 
data (21.3%). Thus, it is reasonable to assume that missingness were at random. Although bias 
could potentially be introduced, analysis of complete data produced results similar to the ones 
generated from imputed data. Estimates for each replicate datasets from the multiple imputation 
also indicated an association between IV alteplase treatment and 1-yr mortality in the same 
direction. 
This study adds more positive results to the existing literature on the impact of IV 
alteplase particularly in the context of its effectiveness and hospitals’ effort to improve the 
overall quality of acute stroke care. The results would help healthcare providers make their 
decision promptly and save valuable time in the care of stroke patients. 
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Conclusions 
The results of this study suggest that patients who are eligible be determined as swiftly as 
possible and those identified as eligible receive the treatment. Besides improvement in function 
and absence of disability, intravenous alteplase administration is associated with reduction in 
long-term mortality. 
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Table 9.  Characteristics of acute ischemic stroke patients eligible for IV alteplase and with 
complete information (n=2925), Georgia Coverdell Acute Stroke Registry, 2008-2013. 
Characteristics 
Treated with 
IV 
ALTEPLASE 
(n=1,937) 
Not Treated with 
IV ALTEPLASE 
(n=988) 
p-valuea 
Age, years, median(IQR) 68 (57, 79) 71 (61, 81.5) 0.0005 
Female, n(%) 990 (51.1) 512 (51.8) 0.72 
Whites, n(%) 1,169 (60.4) 632 (64.0) 0.06 
Medicare as the principal health insurance 
coverage, n(%) 
1,108 (57.2) 653 (66.1) <0.0001 
Brought by EMS, n(%) 1,660 (85.7) 683 (69.1) <0.0001 
NIH Stroke scale score, unit, median(IQR) 11 (7, 18) 5 (3, 12) <0.0001 
Persistent or Paroxysmal Atrial 
Fibrillation/Flutter, n(%) 
472 (24.4) 231 (23.4) 0.55 
Nothing per mouth status 317 (16.4) 100 (10.1) <0.0001 
Medication prior to admission, n(%) 
 Antihypertensive 
 Lipid lowering drug 
 
1,356 (70.0) 
760 (39.2) 
 
766 (77.5) 
448 (45.3) 
 
<0.0001 
0.002 
Medical history of, n(%) 
 Dyslipidemia 
 Diabetes mellitus 
 Hypertension 
 Coronary artery disease (MI) 
 Heart failure 
 Atrial fibrillation/flutter 
 Smoking 
 
751 (38.8) 
521 (26.9) 
1,567 (80.9) 
463 (23.9) 
207 (10.7) 
374 (19.3) 
451 (23.3) 
 
436 (44.1) 
339 (34.3) 
835 (84.5) 
258 (26.1) 
113 (11.4) 
186 (18.8) 
200 (20.2) 
 
0.01 
<0.0001 
0.02 
0.19 
0.54 
0.75 
0.06 
Last known well to hospital arrival time, 
minutes, median(IQR) 
60 (40, 88) 191 (120, 230) <0.0001 
Hospital bed size, n(%) 
 <100 beds 
 100–249 beds 
 250–399 beds 
 >=400 beds 
 
30 (1.5) 
256 (13.2) 
422 (21.8) 
1,229 (63.4) 
 
31 (3.1) 
163 (16.5) 
183 (18.5) 
611 (61.8) 
0.0009 
Admitted on, n(%) 
 Weekend 
 Day time 
 
540 (27.9) 
1,259 (65.0) 
 
282 (28.5) 
614 (62.1) 
 
0.71 
0.13 
Calendar Year, n(%) 
 2008 
 2009 
 2010 
 2011 
 2012 
 2013 
 
142 (7.3) 
198 (10.2) 
306 (15.8) 
343 (17.7) 
441 (22.8) 
507 (26.2) 
 
197 (19.9) 
180 (18.2) 
147 (14.9) 
140 (14.2) 
178 (18.0) 
146 (14.8) 
<0.0001 
One year Outcome, n(%) 
 Mortality 
 Readmission 
 
424 (21.9) 
463 (23.9) 
 
227 (23.0) 
233 (23.6) 
 
0.50 
0.85 
Abbreviation: IQR, Interquartile range 
a χ2 and Wilcoxon tests were applied for nominal and quantitative variables, respectively. 
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Table 10.  Relative risk of 1-year mortality and readmission by intravenous alteplase treatment status, 
Georgia Coverdell Acute Stroke Registry 2008-2013. 
 Complete Data Imputed Data 
Outcome 
Odds Ratio 
(95%CL) 
p-value 
Odds Ratio 
(95%CL) 
p-value 
1-year Mortality 
 Didn’t receive IV alteplase 
 Received IV alteplase 
 
1.12 (0.83,1.67) 
Referent 
0.37 
 
1.49 (1.09, 2.04) 
Referent 
0.01 
1-year Readmission 
 Didn’t receive IV alteplase 
 Received IV alteplase 
 
0.81 (0.48, 1.38) 
Referent 
0.44 
 
0.90 (0.59, 1.39) 
Referent 
0.64 
N.B.:- CL=Confidence limit; IV=Intravenous 
Alteplase treated patients were matched one-to-one with eligible non-treated patients on 
probability of receiving IV alteplase (propensity score), and conditional logistic regression applied 
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Figure 4. Flow diagram for patients included in the analysis 
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CHAPTER V 
SUMMARY 
The three studies demonstrated that registry-based quality improvement is an effective 
strategy to improve the quality of stroke care. Patients treated at hospitals participating in the 
Georgia Coverdell Acute Stroke Registry had a better survival rate than those cared for by 
hospitals not participating in the registry. Among patients treated at GCASR participating 
hospitals, delivery of a better quality care was associated with a lower 1-year mortality. 
Moreover, acute ischemic stroke patients who received intravenous alteplase had a lower 
mortality rate compared to those who were eligible but didn’t receive the treatment. 
In the past two decades, the management of acute stroke has been continuously changing. 
The approval for clot busting drug use in ischemic stroke has revolutionized the treatment 
paradigm from simple palliative care to prevention of death and disability, and control of risk 
factors. But with each scientific discovery to ameliorate the untoward effects of stroke incident 
comes the need for making the new treatment available for patients. Currently, there is a gap 
between what is known as the best care and what is actually being practiced by healthcare 
providers. The national institute of neurological disorders and stroke, in fact, has identified 
translation of scientific discovery as a priority area for its action. 
Researchers have highlighted that the strategy of knowledge translation has evolved from 
a simple passive diffusion where published scientific discoveries are expected to be read, 
understood and assimilated in routine care delivery by practitioners to quality improvement and 
system change.9 In line with this, GCASR, funded by the CDC, adopted the strategy of 
monitoring the quality of stroke care using performance measures. Hospitals modified care 
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processes in their effort to raise their performance measures, and thus improving the quality of 
care stroke patients receive. Performance measures have their own short comings, even when 
there is agreement on what to measure, in terms of complexity of algorithm, clarity of definition 
of data elements feeding to the performance measure, data quality and validity of the measure. 
Nevertheless, they indicate, on average, the quality of care delivered to stroke patients by a 
healthcare facility. 
Performance measures are process indicators and are meant to display quality of service 
at hospital level. They serve for monitoring quality improvement efforts and the progress 
achieved in improving the process of care delivery. In these studies, however, they are also used 
to measure quality of care at a patient level to assess patient outcome. Understandably, the 
results indicate that process indicators may not necessarily capture the essence of quality of care 
adequately to serve as a proxy measure in analyzing impact. Therefore, it is imperative in any 
evaluation of impact of quality of care, appropriate measures are used to capture quality in the 
first place. 
Quality is an abstract concept which cannot be measured directly. The Institute of 
Medicine outlines specific components that constitute quality in a clinical care: safety, 
effectiveness, patient-centeredness, timeliness, efficiency, and equitability.85 It is an arduous 
effort to develop an indicator that encompasses all these aspects of quality in one. Nevertheless, 
there are statistical techniques that would serve to define abstract constructs such as “quality” 
using indicator variables. Therefore, it will be a worthwhile effort to develop latent models using 
either performance measures or any additional patient level information to classify whether a 
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patient, in fact, has received a quality care rather than just adding each performance measure or 
apply an all-or-none rule to measure quality. 
Time is a critical element in the management of stroke patients, and emergency medical 
services play a significant role in identifying and transporting stroke patients to stroke ready 
hospitals. Moreover, how they handle patients with a presumptive diagnosis of stroke has its 
bearing on the subsequent in-hospital care and on patients’ outcome. There are care processes 
that need to be aligned with evidence-based best practices. On the other hand, stroke is an 
overwhelming experience both for patients and their caregivers. Once patients are discharged, 
they require regular follow-ups, either for rehabilitation services or simply to ensure that they 
adhere to the guideline they receive at discharge. Efforts are being made to develop evidence 
based clinical guidelines on the post-hospital care of stroke patients, and there will be a room for 
quality improvement as a strategy to bring those best practices to patient fruition. Thus, it will be 
necessary to evaluate effectiveness of quality improvement efforts both in the pre-hospital and 
post-hospital settings. 
Quality improvement in stroke care is not one single intervention; rather it is a 
multifaceted strategy and comprises of several activities each one with its own effectiveness, 
fidelity in implementation, efficiency, reach and impact on patient outcome. It is critical, 
therefore, to identify elements that are core to the strategy before contemplating to scale-up 
quality improvement to other stroke care facilities or disease conditions. Evaluating a quality 
improvement initiative also requires determining which aspect, which system change, or process 
or outcome should be examined. Given the readily availability of data sources, end results such 
as mortality, disability and readmission give the opportunity to capture the ultimate impact of 
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quality improvement program without discerning how much is contributed by which component. 
These studies, therefore, serve as examples and could be replicated for similar initiatives around 
any disease condition. 
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ANNEX 
Linkage Between The Georgia Coverdell Acute Stroke Registry And The Georgia 
Discharge Data System 
The Georgia Coverdell Acute Stroke Registry (GCASR) data has only non-specific information 
including age, sex, race, date of admission and discharge, and facility code. It has about 200 
variables and more than 10,000 observations per year. It is assumed that the non-specific 
information listed would be sufficient to get a reasonably acceptable yield when the registry is 
linked to hospital discharge (GDDS) data. 
The hospital discharge data are collected for administrative purpose on all patients who are 
hospitalized in non-federal acute care or critical access hospitals in the state of Georgia. The data 
set has about 75 variables and more than a million observations per year. Among the hospital 
discharges, more than fifty thousand are for adults 18 years and older with an ICD 9 code of 
stroke (430-438) in one of the ten diagnosis fields.  
The GCASR and GDDS data do not have a universal patient identifier in common; exact 
matching of several linking variables applied all at once would have insufficient yield because of 
missing values (Table 1) and possible transcription errors. Thus, we applied a hierarchical 
deterministic method with different combinations of the linking variables to maximize linkage 
accuracy and yield while reducing the impact of missing values and errors (Table 2). 
The underlying assumption for linking the GCASR and GDDS data is that no two subjects with 
similar demographic characteristics would be admitted to or discharged from the same facility on 
the same date with acute stroke (Table 3). Once the two data sets were linked, a 15 digit 
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alphanumerical code in the GDDS data, composed of letters from first and last name, birthdate 
and gender code, served as a quasi-unique identifier for each subject. 
Testing Linkage Accuracy 
We used records from the 2010 GCASR and GDDS data for assessing linkage accuracy. In 2010, 
56 GCASR facilities had 11,043 acute stroke admissions. The highest number of admissions per 
facility per day was nine, and 47 hospitals had admitted two or more patients on the same day at 
least once. Among the 2010 discharges from non-federal and non-rehab facilities, 52,272 records 
of adults 18 years and older had an ICD 9 code of stroke (430-438) in one of the diagnosis fields 
and were used for linkage with the GCASR data.  
The registry data is a subset of GDDS data and any subject from GDDS data with similar values 
in the six listed matching characteristics – facility, dates of admission and discharge, age, gender 
and race – would match with the registry data. It is, thus, appropriate and more informative to 
ask how many of the registry data failed to link and whether the linked GCASR records matched 
to the true hospital discharge record. 
In 2010, about 70% of acute stroke patients in Georgia were treated at GCASR participating 
hospitals.1 Assuming an 80% case ascertainment completion rate, the prevalence of GCASR 
reported acute stroke admission in Georgia would be greater than fifty percent. Hence, based on 
the method described by Buderer,2 a sample of 277 subject would be enough to establish a 
sensitivity of 90% with 5% precision at 0.05 level of significance. Considering a two-third 
response rate, we increased the sample size to 430. 
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Hospitals around the Atlanta metro area account for about half ( 52%) of the registry patients. 
Patient records were selected randomly from Atlanta area hospitals with 200 or more discharges 
of acute stroke in 2010. The first and last name, sex and birth date of sampled patients were 
recorded from the original hospital patient chart. The information was then used to construct the 
quasi-unique patient identifier (variable LONGID) that was subsequently compared with the 
same variable from the hospital discharge in the linked data file. The difference in the values of 
sex (between what was initially entered into the registry data and the one reported by hospitals 
for sampled patients) was calculated to quantify simple transcription error in data entry. The 
performance of the data linkage between the GCASR and hospital discharge data was assessed 
among the randomly selected patients’ records using indices of sensitivity and positive predictive 
value. The proportions of registry records linked with GDDS data was analyzed in aggregate and 
separately for each hospital. The Fine–grained record integration and linkage tool (FRIL) 
software version 2.1.5 was used for data linkage.3 
Results 
GCASR had 11,043 records entered from 56 hospitals in 2010; 151 were transferred to another 
facility without admission. Among the 10,892 records, 10,536 had valid values of all the 
variables used for data linkage. Eighteen records had missing value for sex and 340 for race. 
Two hundred thirty-five patients were discharged within 24 hours. The matching algorithm 
resulted in linking 9,530 (88%) of the GCASR records with hospital discharges (Figure 1). 
Concordance in matching variables was greater than 96% between the two data sources (Table 
4). 
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The proportion of linked records varied among hospitals participating in GCASR from 25% to 
99%, the median being 91% with 76% and 94% first and third quartiles, respectively. Though 
not statistically significant, differences were observed among hospitals based on bed size and 
primary stroke center status (Table 5). Large hospitals and primary stroke centers had a relatively 
higher proportion of records matched with the GDDS data. 
Information was gathered for 322 the randomly selected GCASR records. Sex and age were 
different from what was reported in the registry in 13 and 19 of the sampled records, 
respectively. Linkage resulted in 277 (99.6%) true matches and 1 (0.4%) mismatch; the 
remaining 44 were not linked to any record from the hospitalization data (Figure 1). The 
percentage of matched records varied among hospitals with a median of 92% (Q1=86%, 
Q3=96%). 
Discussion 
Results from the study showed that linkage between the registry and GDDS is highly specific. 
There was only one registry record mismatched with the hospital discharge. Examination of the 
record indicated a typographical error where an age 57 was entered instead of 75. The yield, on 
the other hand, is not comparable to the specificity. Nonetheless, given the percent of missing 
values (e.g. 3.3% race in the registry data) and data entry error (e.g. 5% age in registry data) 
observed in matching variables, the result can be considered satisfactorily high. 
Given a 92% sensitivity in a previous study linking GDDS data with death data,4 the yield 
diminishes further when all the three data sources are linked together. We would expect to have 
about 80% (0.91x0.88) yield if we combine the registry data with GDDS and then with the death 
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records. If we are interested in estimating the occurrence of events such as death among patients 
admitted with stroke, we will underestimate the mortality rate. However, if a study aims to assess 
the impact of an intervention, for instance IV tPA treatment, and we compare those who received 
the treatment vis-à-vis those who didn’t, then it is possible to compare mortality rates between 
the two groups, unless there is a reason to believe death in the two groups is captured differently 
by death record. Obviously, there will be a misclassification bias but it will be non-differential 
and will only diminish the effect measure towards the null value. 
The small subset of randomly selected GCASR records showed that matching variables could 
have data entry errors. Depending on the number of variables used for matching, applying exact 
matching in each linking variable would diminish the yield significantly. Therefore, it is 
pragmatic to establish an iterative matching using a couple of blocking variables to maximize the 
return at the end of data linkage. The approach used in this study, the hierarchical deterministic 
linkage, becomes a necessity rather than a choice. 
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Table 1  Percent of missing or implausible values in matching variables among the data sources 
Variable 
GDDS 
(2010) 
GCASR 
Data 
Variable 
GDDS 
(2010) 
Sex 0.0% 0.2%  LONGID 1.6% 
Age 0.0% 0.0%  Birth date 0.0% 
Race 0.0% 3.3%  Residence County 4.3% 
Facility 0.0% 0% Residence ZIP 4.3% 
Discharge date 0.0% 0%   
Admission date 0.0% 1.4%    
GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System 
 
Table 2  Key variables and their combination for matching the 2010 GCASR and GDDS data 
Linkage 
Step 
Linking variable 
Distance metric 
(Approve/Disapprove level) 
Acceptance 
level 
Step I 
Facility 
Admission date 
Age 
Sex 
Equal fields Boolean distance 
Date Distance (+/-  0 day) 
Numeric distance (+/- 0) 
Equal fields Boolean distance 
100%  
Step II 
Facility 
Admission date 
Age 
Race 
Equal fields Boolean distance 
Date Distance (+/- 0 day) 
Numeric distance (+/- 0) 
Equal fields Boolean distance 
100%  
Step III 
Facility 
Discharge date 
Age 
Sex 
Equal fields Boolean distance 
Date Distance (+/- 0 day) 
Numeric distance (+/- 0) 
Equal fields Boolean distance 
100%  
Step IV 
Facility 
Discharge date 
Age 
Race 
Equal fields Boolean distance 
Date Distance (+/- 0 day) 
Numeric distance (+/-0) 
Equal fields Boolean distance 
100%  
Step V 
Facility 
Admission date 
Discharge date 
Race 
Sex 
Equal fields Boolean distance 
Date Distance (+/- 0 day) 
Date Distance (+/- 0 day) 
Equal fields Boolean distance 
Equal fields Boolean distance 
100%  
N.B.:- 
• Facility is the blocking variable 
• GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System 
• Exclude those with 
– Missing admission date 
– Age differences > 1yr 
– Admission date difference > 1 day  
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Table 3  Specificity of combinations of facility, demographic and event related information 
Combination Total Unique Non-specific 
GCASR data (N = 11,043) 
Facility, Admission date, Age 10,881 10,723  158 
Facility, Admission date, Age, Race 10,943 10,844 99 
Facility, Admission date, Age, Sex 10,962 10,884 78 
Facility, Admission date, Age, Race, Sex 10,991 10,940 51 
Facility, Admission date, Age, Race, Sex, 
Discharge date 
11,023 11,003 20 
 
GDDS data (N = 52,272) 
Facility, Admission date, Age 50,855 49,482 1,373 
Facility, Admission date, Age, Race 51,405 50,549 856 
Facility, Admission date, Age, Sex 51,531 50,804 727 
Facility, Admission date, Age, Race, Sex 51,838 51,407 431 
Facility, Admission date, Age, Race, Sex, 
Discharge date 
52,218 52,164 54 
GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System 
 
Table 4  Agreement in matching variables 
Matching Variable 2010 GCASR Vs. GDDS 
NAME* 98.4% 
Birth Date 98.4% 
Age 98.4% 
Sex 99.3% 
Race 96.7% 
Facility 100.0% 
Admission date 96.2% 
Event/Discharge date 97.1% 
GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System 
*: refers to a 6-digit code derived from names 
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Table 5  Average percentages of GCASR records matched with hospital discharges by hospital 
characteristics 
Categories Median 1st. Quartile 3rd. Quartile 
Bed size 
 <= 100 beds 
 101-250 beds 
 251 - 400 beds 
 > 400 beds 
 
79.6% 
87.0% 
92.4% 
91.1% 
 
65.6% 
70.6% 
90.9% 
87.9% 
 
91.9% 
94.9% 
95.0% 
93.9% 
Primary Stroke Center Status 
 PSC 
 Non-PSC 
 
92.0% 
82.9% 
 
87.0% 
66.9% 
 
94.8% 
93.4% 
GCASR: Georgia Coverdell Acute Stroke Registry; PSC: Primary Stroke Center 
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Figure 1. Georgia Coverdell Acute Stroke Registry Records linked with Hospital Discharge data, 2010 
                  
